LSA

Under current federal instruments, LSA falls within the controlled-drug and border-controlled-drug entries for Lysergamides and Lysergamide. NIH PubChem identifies LSA as lysergic acid amide (ergine), and the current Criminal Code Regulations expressly list Lysergamides as controlled drugs and Lysergamide as a border controlled drug. The Commonwealth Poisons Standard—June 2026 commenced 1 June 2026 and remains current until substituted; Schedule 9 is the prohibited-substances schedule and lists LYSERGIC ACID and LYSERGIDE. Section 7 provides that a reference to a substance includes every salt, active principle or derivative (including esters and ethers), and the reader's guide says a Schedule entry includes all salts and derivatives unless otherwise stated, while cautioning that derivative classification turns on structural, pharmacological and toxicological factors. LSA is expressly included in the Criminal Code and Customs schedules through its lysergamide listing. The Poisons Standard does not list an exact separate 'LSA' or 'ergine' row. Customs regulation 5(1) prohibits importation of a listed drug unless the importer has the required licence and drug-specific permission, presents the permission, imports during its period and stays within quantity; regulation 5(2), (2A) and (3) preserve approval and tightly defined prescribed passenger/veterinary and other exceptions. Federal Criminal Code penalties are conduct- and quantity-specific: possession of a controlled drug under section 308.1 carries up to 2 years' imprisonment or 400 penalty units (or both); trafficking under section 302.4 carries up to 10 years or 2,000 penalty units (or both); importing/exporting a border controlled drug under section 307.3 carries up to 10 years or 2,000 penalty units (or both), while the marketable-quantity offence in section 307.2 carries up to 25 years or 5,000 penalty units (or both). The Regulations specify Lysergamides at 0.01 kg commercial and 0.01 g trafficable quantity, and Lysergamide at 0.01 kg commercial and 0.1 g marketable quantity; no marketable quantity is specified for Schedule 1 Lysergamides. As a state example, Victoria's current Act defines a Schedule 9 poison by reference to Schedule 9 of the Poisons Standard, gives the Poisons Standard legal effect through the Poisons Code, and section 36B(2) prohibits unauthorised possession of a Schedule 9 poison (other than a drug of dependence) with a maximum penalty of 10 penalty units. The Poisons Standard expressly warns that Schedule 9 implementation may vary among States and Territories; the Victorian penalty therefore cannot be assumed to apply in every jurisdiction, and whether LSA plant material is itself controlled depends on applicable law. The federal and state maxima are maximum statutory penalties, not automatic sentences; the availability of lawful research/medical authorisations and statutory exceptions depends on the particular conduct and jurisdiction.

The current official BWB consolidation lists lysergide in List I and the 2001 parliamentary explanatory memorandum states that the lists were redrafted without a materially relevant change; its concordance table expressly maps the former name ‘Lyserginezuuramide’ to ‘lysergide’. The prior 2002 consolidated Opiumwet text also placed Lyserginezuuramide in List I and included the specified lysergic-acid amide derivatives. The concordance establishes LSA under the Lyserginezuuramide identity as a List-I substance. Article 2 prohibits bringing a List-I means into or out of the Netherlands, cultivating, preparing, processing, selling, delivering, supplying, transporting, possessing or manufacturing it. Article 10(1) provides up to six months’ detention or a fourth-category fine for a non-intentional Article 2 violation; intentional possession (Article 2(C)) carries up to six years’ imprisonment or a fifth-category fine, intentional handling under Article 2(B) or (D) up to eight years or a fifth-category fine, and intentional import/export under Article 2(A) up to twelve years or a fifth-category fine. Articles 5, 6 and 8 provide only defined professional, legally obtained medical/veterinary, institutional, emergency, scientific/analytical and ministerial-exemption pathways; they do not create a general consumer exception. The List-I classification applies to LSA under the lyserginezuuramide identity established by the historical concordance, not to a different lysergamide, plant material or an unverified product formulation.

The current Polish schedule's Annex 3 section 7 expressly captures every compound derived from delta-9,10-ergolene containing structure II with molecular mass up to 500 u, subject to the listed R1-R4 substitutions; section 7.2 permits R1 hydrogen or alkyl/alkylcarbonyl up to C4, R2 hydrogen or alkyl up to C4/allyl/propargyl, and R3 and R4 hydrogen or the listed small groups, including an unsubstituted primary amide. LSA fits that generic lysergamide description. The schedule separately names LSD ((+)-lysergide) in psychotropic Group I-P and named lysergamides such as ALD-52, ETH-LAD, AL-LAD, 1P-LSD and 1Y-LSD in the NPS material, but those entries do not make LSA uncontrolled. LSA is captured by a generic NPS structural class rather than an exact-name row. Article 4(11a) defines a new psychoactive substance as a natural or synthetic substance acting on the central nervous system, other than a psychotropic substance or narcotic drug, that presents comparable health/social risks or imitates those substances and is specified under Article 44f; Article 44e gives precedence to narcotic-drug or psychotropic classification if an overlap exists. Article 62b(1) makes unauthorized possession of an NPS punishable by a fine; significant quantity carries a fine, restriction of liberty or up to three years' imprisonment under Article 62b(2), while an insignificant amount for own use may be discontinued under Article 62b(3) only on the statutory circumstances and is not legalization. Article 53(1a) covers unlawful production, processing or conversion of an NPS with a fine, restriction of liberty or up to three years; Article 53(2) raises significant-quantity or profit-motivated conduct to a fine plus three to twenty years. Article 55 covers unlawful import, export, transit and intra-EU dealings (fine plus up to five years, with lesser-weight and significant/profit bands); Article 56 covers market introduction or participation (fine plus six months to eight years, lesser-weight up to one year, significant quantity two to twelve years); Articles 58 and 59 cover giving, facilitating or soliciting use, with aggravated minor/profit-motivated ranges. Article 61 separately covers precursor or NPS conduct undertaken to produce an illegal drug, with a fine and up to five years. The schedule does not separately designate morning-glory or Ipomoea plants or seeds as controlled plants, and no blanket plant/seed legality rule is established; the absence of such a rule does not establish that seeds, plants, extracts or mixed products are generally legal. This classification applies to pure LSA/ergine and products whose analytical composition establishes LSA, subject to any other applicable scheduled substance.

Classified as a Class A substance under the Misuse of Drugs Act 1971³⁹, categorized as a precursor to LSD. Class A carries the most severe penalties for possession and supply.

The current CDSA does not expressly name LSA/ergine/lysergic acid amide in its schedules; LSD and lysergic-acid entries are distinct. Health Canada's official guidance warns that schedule classes and broadening terms can capture related substances and provides a status-confirmation process for substances not explicitly listed. The Natural Health Products Regulations and Food and Drugs Act make product treatment depend on the substance, formulation and how it is manufactured, sold or represented; an applicable NHP requires a product licence for sale. The applicable framework does not establish that possession or sale is categorically lawful or unlawful and does not resolve LSA-containing plants, seeds, extracts, preparations, products, importation, provincial rules or other Canadian laws.

The current Act does not expressly list LSA, ergine or lysergic acid amide, and the analogue definition requires a fact-specific finding that a substance has a structure substantially similar to a controlled drug. Section 2 includes any controlled-drug analogue within Class C, but New Zealand legislation does not adjudicate whether LSA meets that test or resolve how a particular seed, plant, extract or preparation would be characterized. Lysergide (LSD) is expressly Class A, and lysergic acid is expressly listed as a Class A drug and a Schedule 4 precursor. The Act's express prohibited-plant definition names Cannabis, Papaver somniferum, specified Erythroxylon, Lophophora and specified fungi; morning glory is not named there, but this does not determine legality under every other New Zealand law. If LSA were legally treated as a Class C analogue, s 7 prohibits procurement, possession and use, with a maximum of 3 months' imprisonment or NZ$500 fine (or both), subject to the statutory limits on custodial sentences and the public-interest prosecution discretion. Section 6 prohibits unlicensed import/export, production/manufacture and specified supply, sale and possession-for-supply conduct; the Class C/other-case maximum is 8 years. Section 29C provides a defence to an analogue-possession charge where the defendant proves a non-pharmacological/non-supply purpose or supply under a Director-General-approved procedure. These are statutory maximums and conditional rules, not a substance-specific ruling that all LSA material is lawful or unlawful. The exact analogue question remains unresolved; the current schedule has no express LSA entry, and the legislation does not determine whether LSA is an analogue.

The current Folkhälsomyndigheten register, updated 14 July 2026, says its table contains substances for which the agency has opined that the government may classify them as narcotics or health-hazardous goods, that it investigates the need for classification, and that substances are removed when the opinion is no longer current; LSA remains in that table with the 2012/28 opinion. The current LVFS 2011:10 consolidated schedule (amendments through HSLF-FS 2026:26) contains no exact LSA, lysergsyraamid, or (8β)-9,10-didehydro-6-metyl-ergolin-8-carboxamid entry; its listed LSD/lysergide and other ergoline derivatives are distinct substances. The current health-hazardous-goods annex likewise contains no LSA or its chemical name. The 2012 official opinion only initiated an investigation and assessed that LSA might later be classified; it is not a classification instrument. Narkotikastrafflag penalties apply to conduct involving narcotics, and Lag (1999:42) penalties apply to goods listed under that health-hazardous-goods regime; because the current schedules do not classify LSA, no LSA-specific criminal penalty applies under those regimes. This status applies only to pure chemical LSA and does not establish the legal status of Ipomoea plants, seeds, or extracts.